Energy Crisis Drives Agricultural Transformation: Opportunities in MustGrow Biologics, K+S, and Corteva Agriscience

K+S Between Cost Pressure and Transformation

As a potash and salt producer, K+S finds itself caught between rising costs and a strategic realignment. As a processor of raw materials, K+S is vulnerable to rising energy costs. In fiscal year 2025, the group generated revenue of approximately EUR 3.7 billion, representing no growth compared to the previous year. The company reported an adjusted consolidated net loss of EUR 1.1 billion, primarily due to an impairment charge of approximately EUR 1.6 billion. Despite these factors, K+S exceeded EBITDA expectations in the fourth quarter of 2025, leading to a surge in the stock price. To counter cost pressures, management is focusing on optimizations at production sites. The Werra 2060 project is intended to ensure efficiency in Germany, while the Canadian site in Bethune is being expanded. A key component of the strategy is the refocus on regenerative soil amendments to increase crop resilience through specialized nutrient combinations.

Corteva Agriscience Accelerates the Shift to Biologicals

Corteva Agriscience is positioning itself as a pioneer in the transition from synthetic chemical to biological crop protection products. The company is leveraging its market power and in-house research to transform its portfolio toward sustainability and innovation. In the past fiscal year, Corteva reported a 3% increase in revenue on an organic basis and achieved net revenue of approximately USD 17.4 billion. Growth was driven primarily by the crop protection segment, where volume rose by 5%, driven by demand for new products and biologics. Corteva's strategy is based on the introduction of differentiated technologies, with 65% of crop protection revenue coming from in-house developments. A milestone was the integration of the acquisitions Symborg and Stoller, which made Corteva one of the largest players in the market for biological agricultural products. Revenue from biologics already stood at around USD 500 million in 2024. Technologically, the company is focusing on platforms such as short-statured corn, which enables more precise nutrient application.

MustGrow Biologics as a Problem Solver in the Crisis

While established corporations are also breaking new ground in the wake of the crisis, MustGrow Biologics offers a direct solution to the supply shortages of synthetic fertilizers. The company has developed a patented technology that uses active ingredients from the mustard plant to improve soil and combat pests. At the center of this approach is TerraSante, an organic soil amendment derived from mustard seeds. Unlike synthetic fertilizers, TerraSante is designed to support the soil microbiome and also stimulates beneficial bacteria and fungi. A healthy microbiome unlocks nutrients bound in the soil, such as phosphorus. Since plants can absorb nutrients more efficiently, the need for synthetic fertilizers decreases significantly, which is a clear advantage in times of natural gas shortages. TerraSante's competitiveness is backed by field trials from last year. In the US state of Washington, a potato farmer achieved a yield increase of 2 tonnes per acre. With product costs of USD 180 per acre, this resulted in an added value of USD 5,000, corresponding to a return on investment of 2,700%.

MustGrow has completed its transition to a commercial provider and already achieved record sales in the US last year. To meet demand, management is establishing production lines in Asia designed to enable economies of scale. The partnership with Bayer in the field of biopesticides is progressing, with Bayer contributing resources for the registration of TerraMG technology. Earlier this year, MustGrow completed a USD 2.0 million capital increase to finance production and market entry in new regions.

MustGrow: A CAD 33 Million Market Cap Presents an Opportunity

For investors, the restructuring of the agricultural landscape offers lucrative options. K+S remains a solid choice for investors speculating on a recovery in margins through efficiency programs. Corteva Agriscience is the core investment for investors who want to benefit from the scaling of the biologics market by a global corporation. MustGrow Biologics provides the solution to the problem of fertilizer shortages, reduces dependence on chemicals, and lowers farmers' fertilizer requirements. If the planned expansion succeeds, MustGrow's stock is likely to offer the greatest opportunities among the companies mentioned, given its low market capitalization of approximately CAD 33 million.